EUVIMEDEUVIMED entdecken
Crossref

A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma

Olivier Demaria iD, Guillaume Habif iD, Marie Vetizou, Laurent Gauthier iD, Romain Remark, Laura Chiossone iD, Constance Vagne iD, Lucas Rebuffet iD, Rachel Courtois iD, Caroline Denis iD, François Le Floch, Marianna Muller und 22 weitere

Science Immunology · 2024

DOI: 10.1126/sciimmunol.adp3720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Olivier Demaria und 33 weiteren Autor:innen. Beteiligte Einrichtung: Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. Hauptthemen laut MEDLINE: Killer Cells, Natural, Interleukin-2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which targets CD20 and was developed for treating B cell non-Hodgkin lymphoma (B-NHL). CD20-NKCE-IL2v boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. Whereas it presented reduced toxicities compared with those commonly associated with T cell therapies, CD20-NKCE-IL2v showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models. CD20-NKCE-IL2v also increased the cell surface expression of NK cell–activating receptors, leading to activity against CD20-negative tumor cells. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that CD20-NKCE-IL2v induces peripheral NK cell homing at the tumor site. CD20-NKCE-IL2v emerges as a potential alternative in the treatment landscape of B-NHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalInterleukin-2AnimalsHumansMiceLymphoma, B-CellCell Line, TumorFemaleXenograft Model Antitumor AssaysLymphoma, Non-HodgkinMice, SCIDMice, Inbred NOD

Substanzen

Interleukin-2

Autor:innen und Institutionen

  • Innate Pharma Research Laboratories, Innate Pharma, Marseille, France.
  • Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
  • APHM, Hôpital de la Timone, Marseille-Immunopôle Profiling Platform, Marseille, France.
  • Paris-Saclay Cancer Cluster, Le Kremlin-Bicêtre, France.
  • Université Paris-Saclay, Gustave Roussy, INSERM, Prédicteurs moléculaires et nouvelles cibles en oncologie, 94800, Villejuif, France.

ORCID-Profile: Olivier Demaria, Guillaume Habif, Laurent Gauthier, Laura Chiossone, Constance Vagne, Lucas Rebuffet, Rachel Courtois, Caroline Denis, Aurélie Maguer, Jean-Baptiste Vallier, Eric Vivier

Förderung

  • European Research Council

Zitieren

APA

Demaria, O., Habif, G., Vetizou, M., Gauthier, L., Remark, R., Chiossone, L., Vagne, C., Rebuffet, L., Courtois, R., Denis, C., Le Floch, F., Muller, M., Girard-Madoux, M., Augier, S., Lopez, J., Carrette, B., Maguer, A., Vallier, J. B., Grondin, G., …, & Vivier, E. (2024). A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma. Science Immunology. https://doi.org/10.1126/sciimmunol.adp3720

Vancouver

Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, et al. A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma. Science Immunology. 2024. doi:10.1126/sciimmunol.adp3720

BibTeX
@article{Demaria2024,
  author = {Demaria, Olivier and Habif, Guillaume and Vetizou, Marie and Gauthier, Laurent and Remark, Romain and Chiossone, Laura and Vagne, Constance and Rebuffet, Lucas and Courtois, Rachel and Denis, Caroline and Le Floch, François and Muller, Marianna and Girard-Madoux, Mathilde and Augier, Séverine and Lopez, Julie and Carrette, Barbara and Maguer, Aurélie and Vallier, Jean-Baptiste and Grondin, Gwendoline and Baron, William and Galluso, Justine and Yessaad, Nadia and Giordano, Marilyn and Simon, Léa and Chanuc, Fabien and Alvarez, Audrey Blanchard and Perrot, Ivan and Bonnafous, Cécile and Represa, Agnès and Rossi, Benjamin and Morel, Ariane and Morel, Yannis and Paturel, Carine and Vivier, Eric},
  title = {A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma},
  journal = {Science Immunology},
  year = {2024},
  doi = {10.1126/sciimmunol.adp3720}
}
Kostenlos starten →